LIVE UPDATES
-HZ8BWjjKjG.jpg "Photo of Pharmaceutical drugs")
Sygen Pharmaceuticals Limited, Nigeria and the ORx Pharmaceuticals Corp, Canada, have partnered with an affiliate of the Toronto Institute of Pharmaceutical Technology, North America, ORX Pharmaceuticals, to establish Sygen-ORx Bioscience Accelerating Healthcare Innovation in Africa.
A statement by the firm said that Sygen-ORx Biosciences aimed at revolutionising healthcare and addressing pharmaceutical drug security challenges through collaborative innovation.
The statement read: “The Toronto Institute of Pharmaceutical Technology, North America’s premier post-graduate institute for pharmaceutical technology and research, is renowned for its commitment to advancing medical science and improving patient care, brings a wealth of expertise and patented technologies in drug development and commercialisation.
"Led by a team of dedicated professionals and guided by a vision of excellence, ORX has consistently delivered transformative therapies across various therapeutic areas, earning recognition as a leader in the pharmaceutical industry.”
Chief Executive Officer, Sygen Pharmaceutical Limited, Mr Charles Ogunwuyi, explained that the joint venture company would focus on the following aspects: “development of improved formulations of generic pharmaceuticals, focusing on products with established clinical efficacy that have already received regulatory approval and achieved substantial commercial success, advancing innovative drug discovery programmes into the regional and global pharmaceutical market.
"Others are reducing cost and increase access to High Quality Branded Generic Medicines in Africa in addition to establishing the joint venture company, Sygen and ORx will provide support to the joint venture company leveraging their expertise gained from global drug discovery research and development and commercialisation and distribution, aiming to accelerate open innovation in early-stage drug discovery.”
Director General, National Agency for Food and Drug Administration and Control, Prof Moji Adeyeye, said it was an honour to witness the partnership between Sygen and ORx Pharmaceuticals.
She noted, “Again, we have to wait two, three, or even four years because developing a new programme doesn’t happen overnight. NAFDAC encourages technology-driven approaches, and about 70 per cent of our processes are digitised.
"With a digitised system, there is greater transparency, reduced corruption, improved productivity, and better outcomes, making it essential to adhere to the final updates and procedures.”
Sygen Pharmaceuticals, known for its pioneering spirit and dedication to scientific rigour, complements ORX’s strengths with its innovative approach to healthcare solutions.
